With further validation by western blot and immunohistochemistry (IHC) analysis, they concluded that urinary exosomal FABP5 could be a potential biomarker that can be used to predict or confirm high-GS PCa prior to prostatectomy. Here, FABP5 is linked to posterior cortical atrophy.